Citations (5)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Jashin J. Wu, Manish Patel, Feng Zeng, Ahong Huang, Xing Pan, Yiwen Cao, Naijun Chen, Huzefa Photowala, Vishvas Garg & Jeff Crowley. (2023) Real-world dose escalation of biologics for moderate-to-severe psoriasis in the United States. Journal of Dermatological Treatment 34:1.
Read now
Read now
Simone Ribero, Michela Ortoncelli, Luca Mastorino, Pietro Quaglino & Paolo Dapavo. (2023) Reduced doses of biological therapies in psoriasis: a new potentially “sustainable” frontier of psoriasis treatment. Expert Opinion on Biological Therapy 23:9, pages 867-868.
Read now
Read now
Articles from other publishers (3)
Andrew Blauvelt, Nianwen Shi, Najwa Somani, Russel Burge, Baojin Zhu, Terri Ridenour, Scott Kern, Carolyn Lew, Nicole Zimmerman & Mwangi Murage. (2023) Comparison of Real-World Costs, Healthcare Resource Utilization, and Comorbidity-Related Costs Between Ixekizumab and Secukinumab Among Biologic-Experienced Patients with Psoriasis Over 18 Months in the USA. Clinical Drug Investigation 43:3, pages 185-196.
Crossref
Crossref
Rani Soenen, Zhigang Wang, Lynda Grine, Erwin Dreesen, Lisa Schots, Els Brouwers, Paul Declerck, Debby Thomas & Jo Lambert. (2022) Therapeutic drug monitoring in dermatology: the way towards dose optimization of secukinumab in chronic plaque psoriasis. Clinical and Experimental Dermatology 47:7, pages 1324-1336.
Crossref
Crossref
Jing Gao, Xue Shen, Randy Ko, Cong Huang & Changbing Shen. (2021) Cognitive Process of Psoriasis and Its Comorbidities: From Epidemiology to Genetics. Frontiers in Genetics 12.
Crossref
Crossref